On June 11, WuXi XDC fell 4.05% in regular trading, trading at 44.92 HKD/share, with trading volume of 18.334 million HKD. The stock has now declined more than 21% below its previous buyback average price of 57.3 HKD, with weakness deepening over consecutive trading sessions.

On the news front, the company previously disclosed that a professional trustee repurchased 5.702 million shares at an average price of 57.3 HKD, totaling approximately 327 million HKD. Parent company WuXi Biologics also announced a buyback plan of up to 400 million USD, bringing the combined WuXi group repurchase scale to 500 million USD. Despite the intensive buyback campaign, selling pressure has not been effectively reversed, with market sentiment remaining subdued.

Within the Life Sciences Tools and Services sector, performance diverged today. WuXi AppTec rose 0.25%, WuXi Biologics fell 1.35%, GenScript Biotech rose 2.41%, XtalPi fell 3.16%, and Insilico fell 3.62%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)